optomap[®] MULTIMODALITY UWF IMAGING THAT IMPROVES CLINICAL PRACTICE





optomap is multimodality imaging technology, able to generate high-resolution 200° ultra-widefield (UWF™) images to visualize vitreoretinal*, retinal and choriodal layers from pole to periphery.¹

- optomap is the only single capture consensus-defined UWF image²
- 4 **opto**map images are captured in less than ½ second through an undilated pupil
- 2500+ peer-reviewed publications in 179 diseases demonstrate the value of **opto**map
- **opto**map use enhances pathology detection, disease management, and clinic flow^{12,3}
- OptosAdvance[™] software streamlines image review and enables images to be overlaid to assess changes overtime

"Optos imaging has revolutionized retina and is indispensable in the management of retinal vascular diseases."

- David M. Brown, MD Retina Consultants of Texas

See how **opto**map will help you manage your patients. For more information call **800-854-3039** or **BDS@optos.com**.





CLINICAL SUMMARY

The ONLY single capture multimodality UWF retinal imaging

- optomap utility has been evaluated for the use across 179 diseases in 2500+ publications demonstrating equivalence with traditional single and multi-capture fundus photos and OCT for:
 - DR & DME4-10
 - AMD and GA¹¹
- ROP¹²
- Uveitis / Vasculitis¹³
- Sickle cell¹⁴
- optomap color rg may allow a better evaluation of:
 - Vascular disease^{1,4-10}
 - RPE chanaes¹
 - Pigment dispersion due to laser¹
 - Deep retinal hemorrhages in diabetic retinopathy^{1,4-10}
 - Nevus¹⁵
 - Myopia^{16,17}
 - Ocular oncology^{16,17}
 - Inflammatory disease^{16,17}
 - Inherited retinal disorders^{16,17}
- optomap color rgb may improve the ability to differentiate1:
 - Optic nerve anatomy
 - Hyaloid reflection
 - PVR subretinal band
 - Peripheral retinal abnormalities (holes, tears, lattice)
 - Superficial retinal hemorrhages
 - Neovascularization
 - Ghost vessels or ischemia
 - Enhanced contrast between the retinopexy
 - Retinoschisis¹⁸
- optomap stereo imaging equivalent for glaucoma assessment¹⁹



- optomap is able to image through cataracts 85% of the time²⁰ and reduces ungradable images in 81%²¹
- optomap af is available in green (532nm) and blue (488nm)* - optomap green af finds peripheral changes in 66%²² across a variety of diseases including 97% of eyes with AMD have peripheral changes²³
 - optomap blue af is obtained in a single capture in a wavelength consistent with clinical trial imaging standards
- optomap fa may be an effective prognostic marker to better predict risk of worsening over time²⁴
 - Higher risk of progression has been associated with areas of nonperfusion greater than 77.5mm^{2 25} or 107.3 disc areas²⁶
- optomap icg visualized peripheral changes in 67% ²⁷
- optomap-guided OCT impacts clinical decision making in 84%28
- optomap implementation reduces patient visit duration 33% (28 minutes)²⁹ allowing 4.4% more patients a year (1.5/ day)³
- 97% of optomap users reported unexpected pathology in a patient with no visual complaints³⁰
- OptosAdvance tools allow for the easy assessment of the progression of lesions using image overlay annotations including: area, diameter and change over time



· Optos devices serve as a work horse device for the busy eye care practice providing multi-wavelength retinal imaging for diagnosis and documentation, streamlining capture and review improving clinic flow and efficiency

National Networks (Network) (Network

* Feature may not be available in all regions, please check with your representative. optomap is available on Daytona, California, Monaco and Silverstone Devices.



Optos UK/Europe +44 (0)1383 843350 ics@optos.com

Optos North America 800 854 3039 usinfo@optos.com

Optos DACH DE: 0800 72 36 805 AT: 0800 24 48 86 CH: 0800 55 87 39 ics@optos.com

Optos Australia +618 8444 6500 auinfo@optos.com

